Previous 10 | Next 10 |
Paratek Pharmaceuticals, Inc. (PRTK) Q1 2019 Earnings Conference Call May 08, 2019 4:30 PM ET Company Participants Ben Strain - Executive Director Investor Relations & Corporate Communications Michael Bigham - Chairman & Chief Executive Officer Adam Woodrow - Chief Commer...
The following slide deck was published by Paratek Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Paratek Pharmaceuticals (NASDAQ: PRTK ): Q1 GAAP EPS of -$1.10 beats by $0.10 . Revenue of $1.6M (+15900.0% Y/Y) beats by $0.83M . Press Release More news on: Paratek Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
-- Approximately One Third of Commercial Lives in U.S. had Access to NUZYRA by the End of the First Quarter 2019 -- -- Significant Presence at ECCMID 2019 with Nine NUZYRA Presentations -- BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a comme...
BOSTON, April 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK ), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
- New microbiology data reinforce activity of NUZYRA against broad range of pathogens commonly associated with community-acquired infections - Study supports no dose adjustments in patients based on BMI AMSTERDAM, The Netherlands, April 15, 2019 (GLOBE NEWSWIRE) -- New data presented at...
WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinica...
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that data from its NUZYRA™ (omadacycline) clinical and mi...
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the scientific team who worked on the clinical development ...
BOSTON, March 28, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the H.C Wainwright Global Life ...
News, Short Squeeze, Breakout and More Instantly...
Paratek Pharmaceuticals Inc. Company Name:
PRTK Stock Symbol:
NASDAQ Market:
Paratek Pharmaceuticals Inc. Website:
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Paratek Pharmaceuticals Inc. (PRTK) is expected to report $-0.25 for Q3 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military ...